Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PC...

Full description

Bibliographic Details
Main Authors: Tal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Journal of Microbiology, Immunology and Infection
Subjects:
COVID-19
Immunocompromised
Tixegavimab/cilgavimab
Remdesivir
Nirmatrelvir
Online Access:http://www.sciencedirect.com/science/article/pii/S1684118223001706

Internet

http://www.sciencedirect.com/science/article/pii/S1684118223001706

Similar Items